239 related articles for article (PubMed ID: 30181558)
1. Structural basis for the complete resistance of the human prion protein mutant G127V to prion disease.
Zheng Z; Zhang M; Wang Y; Ma R; Guo C; Feng L; Wu J; Yao H; Lin D
Sci Rep; 2018 Sep; 8(1):13211. PubMed ID: 30181558
[TBL] [Abstract][Full Text] [Related]
2. Structural effects of the highly protective V127 polymorphism on human prion protein.
Hosszu LLP; Conners R; Sangar D; Batchelor M; Sawyer EB; Fisher S; Cliff MJ; Hounslow AM; McAuley K; Leo Brady R; Jackson GS; Bieschke J; Waltho JP; Collinge J
Commun Biol; 2020 Jul; 3(1):402. PubMed ID: 32728168
[TBL] [Abstract][Full Text] [Related]
3. Disassociation of β1-α1-β2 from the α2-α3 domain of prion protein (PrP) is a prerequisite for the conformational conversion of PrP
Chandrasekaran P; Santosh Kumar C; Rangachari K; Sekar K
Int J Biol Macromol; 2019 Sep; 136():368-376. PubMed ID: 31207327
[TBL] [Abstract][Full Text] [Related]
4. Mutation-Dependent Refolding of Prion Protein Unveils Amyloidogenic-Related Structural Ramifications: Insights from Molecular Dynamics Simulations.
Palaniappan C; Narayanan RC; Sekar K
ACS Chem Neurosci; 2021 Aug; 12(15):2810-2819. PubMed ID: 34296847
[TBL] [Abstract][Full Text] [Related]
5. Atomic insight into prion disorder: An intricate detail gained by 0.5 μs molecular dynamics simulation of preventive G127V and deleterious D178V mutation in prion protein.
Gharemirshamlu FR; Bamdad K; Naeimi S
J Cell Biochem; 2019 Aug; 120(8):14156-14164. PubMed ID: 30977169
[TBL] [Abstract][Full Text] [Related]
6. Protective V127 prion variant prevents prion disease by interrupting the formation of dimer and fibril from molecular dynamics simulations.
Zhou S; Shi D; Liu X; Liu H; Yao X
Sci Rep; 2016 Feb; 6():21804. PubMed ID: 26906032
[TBL] [Abstract][Full Text] [Related]
7. The G127V variant of the prion protein interferes with dimer formation in vitro but not in cellulo.
Sangeetham SB; Engelke AD; Fodor E; Krausz SL; Tatzelt J; Welker E
Sci Rep; 2021 Feb; 11(1):3116. PubMed ID: 33542378
[TBL] [Abstract][Full Text] [Related]
8. The G126V Mutation in the Mouse Prion Protein Hinders Nucleation-Dependent Fibril Formation by Slowing Initial Fibril Growth and by Increasing the Critical Concentration.
Sabareesan AT; Udgaonkar JB
Biochemistry; 2017 Nov; 56(44):5931-5942. PubMed ID: 29045139
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics studies on the buffalo prion protein.
Zhang J; Wang F; Chatterjee S
J Biomol Struct Dyn; 2016; 34(4):762-77. PubMed ID: 26043781
[TBL] [Abstract][Full Text] [Related]
10. Toward the molecular basis of inherited prion diseases: NMR structure of the human prion protein with V210I mutation.
Biljan I; Ilc G; Giachin G; Raspadori A; Zhukov I; Plavec J; Legname G
J Mol Biol; 2011 Sep; 412(4):660-73. PubMed ID: 21839748
[TBL] [Abstract][Full Text] [Related]
11. A valine-to-lysine substitution at position 210 induces structural conversion of prion protein into a β-sheet rich oligomer.
Kakuda K; Yamaguchi KI; Kuwata K; Honda R
Biochem Biophys Res Commun; 2018 Nov; 506(1):81-86. PubMed ID: 30336980
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing Mutations Significantly Inhibit Amyloid Formation by Human Prion Protein and Decrease Its Cytotoxicity.
Huang JJ; Li XN; Liu WL; Yuan HY; Gao Y; Wang K; Tang B; Pang DW; Chen J; Liang Y
J Mol Biol; 2020 Feb; 432(4):828-844. PubMed ID: 31821812
[TBL] [Abstract][Full Text] [Related]
13. Y225A induces long-range conformational changes in human prion protein that are protective in Drosophila.
Myers RR; John A; Zhang W; Zou WQ; Cembran A; Fernandez-Funez P
J Biol Chem; 2023 Jul; 299(7):104881. PubMed ID: 37269948
[TBL] [Abstract][Full Text] [Related]
14. Residue-specific mobility changes in soluble oligomers of the prion protein define regions involved in aggregation.
Glaves JP; Ladner-Keay CL; Bjorndahl TC; Wishart DS; Sykes BD
Biochim Biophys Acta Proteins Proteom; 2018 Sep; 1866(9):982-988. PubMed ID: 29935976
[TBL] [Abstract][Full Text] [Related]
15. Dominant-negative effects in prion diseases: insights from molecular dynamics simulations on mouse prion protein chimeras.
Cong X; Bongarzone S; Giachin G; Rossetti G; Carloni P; Legname G
J Biomol Struct Dyn; 2013; 31(8):829-40. PubMed ID: 22934595
[TBL] [Abstract][Full Text] [Related]
16. Effects of the pathological E200K mutation on human prion protein: A computational screening and molecular dynamics approach.
Gharemirshamloo FR; Majumder R; Kumar S U; Doss C GP; Bamdad K; Frootan F; Un C
J Cell Biochem; 2023 Feb; 124(2):254-265. PubMed ID: 36565210
[TBL] [Abstract][Full Text] [Related]
17. Structural mechanisms of oligomer and amyloid fibril formation by the prion protein.
Sengupta I; Udgaonkar JB
Chem Commun (Camb); 2018 Jun; 54(49):6230-6242. PubMed ID: 29789820
[TBL] [Abstract][Full Text] [Related]
18. Destabilizing polymorphism in cervid prion protein hydrophobic core determines prion conformation and conversion efficiency.
Hannaoui S; Amidian S; Cheng YC; Duque Velásquez C; Dorosh L; Law S; Telling G; Stepanova M; McKenzie D; Wille H; Gilch S
PLoS Pathog; 2017 Aug; 13(8):e1006553. PubMed ID: 28800624
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of misfolding of the human prion protein revealed by a pathological mutation.
Sanz-Hernández M; Barritt JD; Sobek J; Hornemann S; Aguzzi A; De Simone A
Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33731477
[TBL] [Abstract][Full Text] [Related]
20. A naturally occurring variant of the human prion protein completely prevents prion disease.
Asante EA; Smidak M; Grimshaw A; Houghton R; Tomlinson A; Jeelani A; Jakubcova T; Hamdan S; Richard-Londt A; Linehan JM; Brandner S; Alpers M; Whitfield J; Mead S; Wadsworth JD; Collinge J
Nature; 2015 Jun; 522(7557):478-81. PubMed ID: 26061765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
